Fulgent Genetics FLGT is getting ready to launch its quarterly earnings on Friday, 2025-05-02. This is a quick overview of what traders ought to be mindful earlier than the announcement.
Analysts anticipate Fulgent Genetics to report an earnings per share (EPS) of $-0.13.
The announcement from Fulgent Genetics is eagerly anticipated, with traders looking for information of surpassing estimates and favorable steering for the following quarter.
It is price noting for brand new traders that steering could be a key determinant of inventory worth actions.
Efficiency in Earlier Earnings
The corporate’s EPS beat by $0.16 within the final quarter, resulting in a 0.0% drop within the share worth on the next day.
Market Efficiency of Fulgent Genetics’s Inventory
Shares of Fulgent Genetics have been buying and selling at $17.35 as of April 30. During the last 52-week interval, shares are down 19.86%. Provided that these returns are usually destructive, long-term shareholders are possible slightly upset going into this earnings launch.
Analyst Views on Fulgent Genetics
For traders, greedy market sentiments and expectations within the business is important. This evaluation explores the most recent insights relating to Fulgent Genetics.
A complete of 1 analyst rankings have been acquired for Fulgent Genetics, with the consensus ranking being Impartial. The common one-year worth goal stands at $16.0, suggesting a possible 7.78% draw back.
Evaluating Scores Amongst Trade Friends
On this evaluation, we delve into the analyst rankings and common 1-year worth targets of Talkspace, Fortress Biosciences and Nutex Well being, three key business gamers, providing insights into their relative efficiency expectations and market positioning.
- Analysts at the moment favor an Purchase trajectory for Talkspace, with a median 1-year worth goal of $5.0, suggesting a possible 71.18% draw back.
- Analysts at the moment favor an Outperform trajectory for Fortress Biosciences, with a median 1-year worth goal of $37.0, suggesting a possible 113.26% upside.
- Analysts at the moment favor an Purchase trajectory for Nutex Well being, with a median 1-year worth goal of $87.5, suggesting a possible 404.32% upside.
Overview of Peer Evaluation
The peer evaluation abstract affords an in depth examination of key metrics for Talkspace, Fortress Biosciences and Nutex Well being, offering worthwhile insights into their respective standings throughout the business and their market positions and comparative efficiency.
| Firm | Consensus | Income Progress | Gross Revenue | Return on Fairness |
|---|---|---|---|---|
| Fulgent Genetics | Impartial | 8.10% | $31.85M | -0.52% |
| Talkspace | Purchase | 14.86% | $21.53M | 1.03% |
| Fortress Biosciences | Outperform | 30.54% | $70.13M | 2.14% |
| Nutex Well being | Purchase | 269.77% | $141.63M | 59.67% |
Key Takeaway:
Fulgent Genetics ranks on the backside for Income Progress and Gross Revenue, whereas it’s within the center for Return on Fairness. The corporate’s efficiency is beneath common in comparison with its friends by way of income development and gross revenue, however it’s comparatively higher by way of return on fairness.
About Fulgent Genetics
Fulgent Genetics Inc is a know-how firm that focuses on genetic testing to offer physicians with clinically actionable diagnostic info. The corporate is engaged in laboratory companies enterprise and a therapeutic growth enterprise. The laboratory companies enterprise which generates key income contains, technical laboratory companies {and professional} interpretation of laboratory outcomes by licensed physicians. Its therapeutic growth enterprise is targeted on growing drug candidates for treating a broad vary of cancers. The geographical segments are the US, which generates the overwhelming majority of the income; and International.
A Deep Dive into Fulgent Genetics’s Financials
Market Capitalization: With restricted market capitalization, the corporate is positioned beneath business averages. This displays a smaller scale relative to friends.
Income Progress: Fulgent Genetics’s outstanding efficiency in 3 months is obvious. As of 31 December, 2024, the corporate achieved a formidable income development fee of 8.1%. This signifies a considerable improve within the firm’s top-line earnings. When in comparison with others within the Well being Care sector, the corporate faces challenges, attaining a development fee decrease than the typical amongst friends.
Internet Margin: The corporate’s internet margin is a standout performer, exceeding business averages. With a formidable internet margin of -7.73%, the corporate showcases robust profitability and efficient price management.
Return on Fairness (ROE): Fulgent Genetics’s ROE excels past business benchmarks, reaching -0.52%. This signifies sturdy monetary administration and environment friendly use of shareholder fairness capital.
Return on Belongings (ROA): Fulgent Genetics’s ROA excels past business benchmarks, reaching -0.48%. This signifies environment friendly administration of belongings and powerful monetary well being.
Debt Administration: Fulgent Genetics’s debt-to-equity ratio is beneath the business common. With a ratio of 0.01, the corporate depends much less on debt financing, sustaining a more healthy stability between debt and fairness, which may be considered positively by traders.
To trace all earnings releases for Fulgent Genetics go to their earnings calendar on our website.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
